Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report

Pseudo-progression with osimertinib after definitive chemoradiation in unresectable epidermal growth factor receptor mutation positive of stage III non-small cell lung cancer: A case report

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) have been widely used in the treatment of locally advanced non-small cell lung cancer (NSCLC). The phenomenon of pseudoprogression in targeted therapy in EGFR-mutation NSCLC patients is rare. Here, we reported an EGFR-mutation-p...

Full description

Bibliographic Details
Main Authors: Fei Ren, Yao Wang, Yongsheng Gao, Xiangjiao Meng
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-08-01
Series:Frontiers in Oncology
Subjects:
pseudoprogression
osimertinib
EGFR mutation
NSCLC
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.971192/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.971192/full

Similar Items